DS-8201: Data from P3 DESTINY-Breast02 trial (NCT03523585) for pre-treated HER2 breast cancer in 2021 (AstraZeneca) - Oct 24, 2019 - Q3 2019 Results: Data from P3 DESTINY-Breast03 trial (NCT03529110) for HER2-positive, unresectable and/or metastatic breast cancer in 2021
P3 data
|